- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BMS 540215 | BMS-540215
Compound class: Synthetic organic
Comment: Brivanib (BMS-540215) is a potent ATP-competitive inhibitor of VEGFR2. Its discovery is reported in .
The International Non-proprietary Name (INN) brivanib alaninate has PubChem CID 11154925, and this represents the prodrug used in clinical trials.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Brivanib progressed to Phase 3 clinical trials for liver and colorectal cancers. Click here to link to ClinicalTrials.gov's complete list of brivanib trials. Treatment with brivanib has been linked to an increased risk of developing fatal adverse events in hepatocellular carcinoma patients in a meta-analysis report .|
|Mechanism Of Action and Pharmacodynamic Effects|
|Like other angiokinase inhibitors, brivanib's anti-neoplastic effect is due to its suppression of the neo-angiogenesis required for tumour growth and expansion .|